Topical formulations for treatment or prevention of skin itch and dryness

By using nucleophilic compounds to form covalent bonds with urea in topical formulations, the carbamylation reaction is inhibited, thus solving the problem of skin itching and dryness caused by urea in uremic pruritus. This achieves moisturizing and soothing effects on the skin while avoiding additional stress on the kidneys.

CN118984702APending Publication Date: 2024-11-19MC2 THERAPEUTICS LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202380032320.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-06
Filing Date
2023-04-04
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Existing technologies have failed to effectively address the skin itching and dryness caused by high concentrations of urea in uremic pruritus, and traditional treatment methods have limited effectiveness.

Method used

Topical formulations containing compounds with nucleophilic groups inhibit carbamylation reactions by forming covalent bonds with urea, thereby reducing the adverse effects of urea on the skin.

Benefits of technology

It effectively reduces the denaturing effect of urea on the skin, improves the skin's moisturizing function, and reduces skin itching. It is suitable for uremic pruritus and other skin diseases, and does not increase the burden on the kidneys.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005069442360000031
    Figure BDA0005069442360000031
  • Figure BDA0005069442360000071
    Figure BDA0005069442360000071
  • Figure BDA0005069442360000081
    Figure BDA0005069442360000081
Patent Text Reader

Abstract

Compounds comprising nucleophiles are provided for use in topical formulations for the treatment or prevention of urea-induced skin itch dryness, such as in uremic pruritus, in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to topical preparations for treating or preventing itchy, dry skin caused by urea. Background Art

[0002] Uremic pruritus (also known as chronic kidney disease-associated pruritus) is one of the most distressing symptoms of renal failure. It affects up to 50% of dialysis patients (l). The skin of uremic patients is often pale, dry and scratchy due to anemia. The condition may include skin symptoms such as eczema, nodular prurigo, nummular eczema and lichenification. Subjective symptoms include intense itching and burning, which may be localized or systemic. There are many hypotheses about the cause of the condition, and several systemic and topical treatments have been developed. In general, these treatments have little or no effect, although some may help subgroups of patients (l).

[0003] The metabolic and endocrine changes in uremic dialysis patients are numerous and complex (2). The accumulation of urea in the body is one of the central metabolic changes in chronic kidney disease. Urea is excreted both through the renal system and through sweat (3). The concentration in sweat is 2-4 times higher than that in serum. This means that high concentrations of urea may be present on the skin of uremic patients (4). Sometimes the concentration is so great that the urea can be seen as uremic frost.

[0004] The stratum corneum is the outer layer of the skin, consisting of a layer of cornified epithelial cells, in the form of protein-rich corneocytes, embedded in a lipid intercellular matrix composed of ceramides, cholesterol and free fatty acids, and mixed with natural moisturizing factors (NMF) (5)(6). Fifty percent of the NMF is composed of amino acids produced by enzymatic breakdown of epidermal proteins, especially filaggrin (6), and its key amino acid degradation products include histidine, trans-urocanic acid and pyrrolidone carboxylic acid (7). The remainder of the NMF is composed of sweat components, including electrolytes, lactic acid, urea and small amounts of additional amino acids. In addition to their moisturizing effects (water binding), amino acids are also part of the natural UV protection (trans-urocanic acid) and act as pH stabilizing factors.

[0005] Individuals with truncating mutations in the gene encoding filaggrin are strongly predisposed to severe forms of dry skin, ichthyosis vulgaris, and / or eczema. It has been shown that almost 50% of all severe eczema cases may have at least one mutated filaggrin gene. The barrier defects seen in filaggrin null carriers also appear to contribute to increased susceptibility and exacerbation of asthma.

[0006] High levels of urea have long been used in both biochemical research and industrial processes for their ability to denature proteins (8). The denaturing effect of urea on globulins is due to the stabilization of the unfolded form of the protein molecule. Urea also has a direct concentration-dependent effect on amino acids at room temperature (8). Small amounts of cyanate present in aqueous urea solutions can add to the -NH 2 The -SH group is present, thereby generating a carbamoyl derivative (9). It has been shown that the logarithm of the rate constant for the reaction between cyanate and an amino acid is linearly related to the pKa value of the amino group of the amino acid or peptide (15).

[0007] Therefore, the increased urea concentration in the stratum corneum of uremic patients (urea comes from sweat) is expected to have a profound effect on enzymatic biological processes in the epidermis and stratum corneum. Excessively high levels of urea-induced protein denaturation combined with pH disruption offset the moisturizing benefits obtained with more normal levels of urea. These effects have not been investigated as a causal factor in uremic pruritus, nor have they been considered as a new approach to treat the condition. The denaturing effect of urea, at the concentrations present in uremic patients, is expected to have a profound effect on the formation of NMFs. The denaturation of proteins (particularly filaggrin) is necessarily expected to reduce filaggrin-derived amino acids, which constitute the majority of the NMF and pH regulating mechanisms in the stratum corneum. In addition, any available histidine will not be converted to trans-urocanic acid because the required enzyme (histidase) can also be denatured by the high urea concentrations in the skin of uremic patients. Histidine itself will be altered by the direct action of urea on the molecule. These interferences that are expected to significantly affect the quantity and quality of NMFs have not been previously studied because the knowledge and kinetics of the formation and biological effects of NMFs are new.

[0008] Regarding the prior art US2016 / 0008297, a topical preparation for treating or preventing skin itching associated with kidney disease is disclosed. There is no disclosure for isolating the nucleophilic attack of urea, and the amino acids used in the preparation are not included as nucleophiles.

[0009] US20150252035 mentions treating pruritus associated with uremic pruritus and several other skin disorders, but the disclosed TRPV4 inhibitors are unable to sequester ureas by acting as nucleophiles.

[0010] US2009 / 0186853 discloses a histidine derivative and an N-propionyl derivative of an amino acid that can treat pruritus. However, there is no disclosure of treating itchy and dry skin by sequestering urea with a nucleophile. In contrast, US2009 / 0186853 mentions that urea can be included in the formulation. Summary of the invention

[0011] The object of the present invention is to provide a formulation for the treatment or prevention of itchy dry skin caused by urea which has improved properties and is mild to the patient's skin.

[0012] Without being bound by any theory, the inventors have found that the adverse effects of excessive urea accumulation on the skin of patients with uremic pruritus can be counteracted by the presence of a compound having a nucleophilic group. Therefore, the present invention relates to a topical preparation for treating or preventing itchy and dry skin caused by urea, wherein the topical preparation comprises a compound of the following formula 1 or a pharmaceutically acceptable salt thereof

[0013]

[0014] R 1 and R 2 Selected from H, C 1 -C 6 Alkyl, or R 1 or R 2 With R 3 or R 4 Together they form a substituted or unsubstituted 3 to 6 membered ring

[0015] R 3 and R 4 Selected from H, C 1 -C 6 Alkyl, halogen, (C 1 -C 6 Alkyl) halogen, (C 1 -C 6 alkyl)COOR 5 , (C 1 -C 6 alkyl)CONHR 5 , (C 1 -C 6 Alkyl)NR 5 R 5 , (C 1 -C 6 Alkyl)OR 5 , (C 1 -C 6 Alkyl)SR 5 , substituted or unsubstituted (C 1 -C 6 alkyl)aryl, substituted or unsubstituted (C 1 -C 6 alkyl)heteroaryl, or R 3 or R 4 With R 1 or R 2 together to form a substituted or unsubstituted 3 to 6 membered ring, or R 3 With R 4Together they form a substituted or unsubstituted 3 to 6 membered ring

[0016] R 5 Select from H or C 1 -C 6 alkyl

[0017] A is (CHR 6 ) n , where n = 0-2, and R 6 Selected from H, OH, OR 5 NR 5 R 5 , halogen or C 1 -C 6 alkyl

[0018] X 1 Selected from CHR 5 or CO

[0019] X 2 Selected from O or NH

[0020] And among them, A, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X 1 and X 2 In each case, they are independent of each other, and wherein at least one group is a nucleophile under physiological conditions. More than one nucleophilic moiety may be present on the nucleophilic compound, optionally more than one nucleophilic moiety of a different type. In a preferred embodiment, the term "substituted" means a group selected from the following: C 1 -C 6 Alkyl, halogen, OR 5 、OCF 3 NR 5 R 5 , cyano, (C 1 -C 6 Alkyl) halogen, (C 1 -C 6 alkyl)COOR 5 , (C 1 -C 6 alkyl)CONHR 5 , (C 1 -C 6 Alkyl)NR 5 R 5 , (C 1 -C 6 Alkyl)OR 5 , (C 1 -C 6Alkyl)SR 5

[0021] In a preferred embodiment, R 1 or R 2 With R 3 or R 4 Together they form a 3 to 6 membered ring selected from the group consisting of aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, tetrahydroimidazolyl, tetrahydrooxazolyl, tetrahydroisoxazolyl, tetrahydrothiazolyl, tetrahydropyrazolyl, piperazinyl or morpholinyl.

[0022] In a preferred embodiment, R 3 With R 4 together form a 3 to 6 membered ring selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydroimidazolyl, tetrahydrooxazolyl, tetrahydroisoxazolyl, tetrahydrothiazolyl, tetrahydropyrazolyl, morpholinyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, thiiranyl, thietanyl, thiolanyl or thianyl.

[0023] In an embodiment of the topical formulation, R 1 and R 2 Selected from H or methyl.

[0024] In topical preparations, R 3 and R 4 Selected from H, C 1 -C 6 Alkyl, (C 1 -C 6 alkyl)COOR 5 , (C 1 -C 6 alkyl)CONHR 5 , (C 1 -C 6 Alkyl)NR 5 R 5 , (C 1 -C 6 Alkyl)OR 5 , substituted or unsubstituted (C 1 -C 6 alkyl)aryl, substituted or unsubstituted (C 1 -C 6 alkyl)heteroaryl.

[0025] Topical preparations for use according to the invention also include those wherein R 1 or R2 With R 3 or R 4 Together they form a substituted or unsubstituted 5- or 6-membered ring.

[0026] In an embodiment of the topical formulation, R 5 It is H or methyl.

[0027] The topical formulations for use according to the invention include embodiments wherein n is 0 or 1, preferably n is 0.

[0028] In an embodiment of the topical preparation for use according to the invention, R 6 Is OH or OR 5 , and preferably R 6 It's OH.

[0029] Topical preparations also include those wherein X 1 is CO and X 2 It is an implementation method of O.

[0030] The topical preparation for use according to the present invention also provides the following embodiments: wherein R 1 One of them is H and R 2 is H, and the other R 1 With R 3 or R 4 together to form an unsubstituted pyrrolidinyl group; most preferably, R 1 and R 2 It's H.

[0031] Formula 1 may also include the following embodiments, wherein R 3 or R 4 One of them is H and the others are selected from H, C 1 -C 6 Alkyl, (C 1 -C 6 alkyl)COOR 5 , (C 1 -C 6 alkyl)CONHR 5 , (C 1 -C 6 Alkyl)NR 5 R 5 , (C 1 -C 6 Alkyl)OR 5 , substituted or unsubstituted (C 1 -C 6 alkyl)aryl, substituted or unsubstituted (C 1 -C 6 alkyl) heteroaryl; preferably, R 3 or R 4One of them is H and the other is C1-C6 alkyl or (C1-C6 alkyl)CONHR 5 .

[0032] The compounds described herein may contain several asymmetric centers and may exist as optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates. Where the compound is a naturally occurring dipeptide, the preferred form is generally the L-configuration.

[0033] In preferred embodiments, the compound and / or pharmaceutically acceptable salt thereof has no more than three nucleophilic groups, more preferably no more than two nucleophilic groups, and most preferably a single nucleophilic group.

[0034] In a preferred embodiment of the topical formulation for use according to the invention, the compound and / or its pharmaceutically acceptable salt has a molecular weight < 1000 Da. In this way, the preparation is easy to handle and manufacture.

[0035] In a preferred embodiment of the topical formulation for use according to the invention, the compound and / or its pharmaceutically acceptable salt also has a water solubility greater than 1% (w / w). This facilitates handling, formulation manufacture and allows for achieving appropriate dosage levels.

[0036] In a preferred embodiment of the topical formulation for use according to the invention, the compound and / or its pharmaceutically acceptable salt also has a stability of >80%, more preferably >90%, in aqueous medium after 1 month at 40° C. This enables the formulation of industrially marketable dosage forms, since less than 20%, such as less than 10%, of the compound degrades after storage in aqueous medium at 40° C. for 1 month.

[0037] In a more preferred embodiment of the topical formulation for use according to the invention, the compound and / or its pharmaceutically acceptable salt also has a stability of >95% in aqueous medium after 3 months at 40° C. This enables the formulation of stable and industrially marketable dosage forms, since less than 5% of the compound degrades after storage in aqueous medium at 40° C. for 3 months.

[0038] In a preferred embodiment, at least one nucleophilic moiety is preferably present in its unprotonated form.

[0039] The topical formulation is used for treating or preventing itchy dry skin caused by urea, and in an embodiment the itchy dry skin caused by urea is selected from the group consisting of uremic pruritus, urostomal dermatitis, incontinence dermatitis, diaper dermatitis.

[0040] As described, the present invention provides a topical formulation for use in treating uremic pruritus. In particular, the present invention provides a topical formulation for use in treating uremic pruritus in a subject, wherein the topical formulation comprising the active compound of Formula 1 and / or its derivatives is applied to the skin at the following concentration range of the compound and / or its derivatives: 0.001 mg / cm 2 and 5mg / cm 2 Between skin surfaces, preferably 0.003 mg / cm 2 and 1mg / cm 2 Between skin surfaces, more preferably 0.005 mg / cm 2 and 0.5mg / cm 2 Skin surface. The compound and / or its derivative may be the only active ingredient in the pharmaceutical composition. Alternatively, the formulation includes more than one active compound of Formula 1.

[0041] Uremic pruritus is a distinct indication that can be clearly distinguished from inflammatory skin diseases (particularly chronic inflammatory skin diseases) such as atopic dermatitis, various types of psoriasis (including plaque flexural, guttate, pustular, nail, photosensitive, erythrodermic psoriasis, and psoriatic arthritis), acne, ichthyosis, contact dermatitis, eczema, photodermatoses, and xerosis.

[0042] According to an embodiment, the topical formulations may also be used to treat or prevent pruritus in aged skin of elderly individuals.

[0043] In topical formulations, the active compounds act by inhibiting carbamylation in the patient's skin, and preferably the compounds produce a BSA carbamylation degree of less than 80%, preferably less than 70%, more preferably less than 60%, even more preferably less than 50%, as measured by the in vitro protein carbamylation assay provided herein.

[0044] Nucleophilic compounds are believed to scavenge cyanates / isocyanates via formation of a covalent bond between the nucleophile and the cyanate / isocyanate, thereby inhibiting carbamylation. Preferably, the covalent bond is irreversible. As used herein, the term irreversible refers to a reaction that cannot be reversed back to the reactants to any significant extent under normal physiological conditions in the human body. Preferably, the nucleophilic moiety is a primary amine.

[0045] In preferred topical formulations for use in the present invention, the compound is selected from the group consisting of N-β-aminoethyl-Gly, Lys-Pro, Val-Pro, Ile-Pro, Tyr-Pro, Ala-Gln, Ala-Glu, Tyr-Ala, Val-Tyr, Gly-Ser, Gly-His and Aspartame.

[0046] In the topical preparation, the compound and / or a pharmaceutically acceptable salt thereof is present in the topical preparation in an amount of between 0.1% (w / w) and 20.0% (w / w), preferably between 0.2% (w / w) and 5.0% (w / w), more preferably between 0.3% (w / w) and 4.0% (w / w) or between 0.5% (w / w) and 20.0% (w / w), preferably between 1% (w / w) and 10% (w / w), more preferably between 2% (w / w) and 5.0% (w / w).

[0047] Specific embodiments of the present invention

[0048] The present invention will now be described in further detail with reference to some examples.

[0049] A number of compounds according to Formula 1 have been tested in in vitro assays for their ability to inhibit the urea-derived carbamylation of the model protein bovine serum albumin (BSA).

[0050] As can be seen from the table below, a series of compounds according to the formula have the ability to reduce or inhibit the carbamylation of BSA caused by urea.

[0051] The test was performed as described below.

[0052] 200 μL of 0.5% BSA solution, 200 μL of test solution and 100 μL of 5 μCi / mL 14C-potassium cyanate solution were mixed in an Eppendorf tube (corresponding to a final concentration of 75 μM BSA, 25 μM 14C-potassium cyanate and 10 mM nucleophile). The samples were run in triplicate (n=3). The Eppendorf tube was incubated at 37°C for 72 hours.

[0053] After incubation, each sample of 100 μL volume was transferred to a new Eppendorf tube containing 100 μL of 10% trichloroacetic acid (TCA) and stored at 4 ° C overnight (for precipitation of BSA). Subsequently, the precipitated BSA was separated from the buffer by centrifugation (10000 rpm, 30 seconds). The supernatant was removed and the BSA particles 10 were resuspended in 200 μL of 10% cold TCA (4 ° C) solution. The particles were recovered by centrifugation (10000 rpm, 30 seconds) and the supernatant was discarded. The BSA particles were resuspended in 100 μL of pure water (MilliQ) and transferred to a scintillation bottle. The Eppendorf tube (previously containing BSA particles) was rinsed with an additional 100 μL of pure water and transferred to the relevant scintillation bottle. For scintillation 15 counting, 2 ml of scintillation fluid (UltimaGold, PerkinElmer) was added to each scintillation bottle and scintillation counting was performed on a TRI-Carb2910 scintillation counter (PerkinElmer). The results for different compounds are shown in Tables 1 and 2 below.

[0054] Table 1. Results of in vitro protein carbamylation assays with different nucleophiles

[0055]

[0056]

[0057] Table 2. Results of in vitro protein carbamylation assays with different nucleophiles

[0058]

[0059]

[0060] Thus, it is apparent that compounds according to Formula 1 having at least one nucleophilic group are capable of reducing carbamylation caused by urea. Furthermore, it is apparent that dipeptides and dipeptide derivatives are generally significantly more potent than simple amino acids and are therefore more likely to be better urea-derived isocyanate scavengers than single amino acids.

[0061] As described above under the heading "Summary of the Invention", the inventors have discovered that the site of action may be primarily on the patient's skin. Without being bound by theory, excess urea will be primarily excreted from the sweat gland ducts and may be reabsorbed. Treatment with topical preparations typically involves application to a compromised skin barrier, which is likely for pruritus dry skin caused by urea, because of carbamylation and mechanical damage caused by the patient's itch, such a compromised skin barrier will be inherently more permeable than intact healthy skin. There is a desire here to deliver active compounds non-dermally. Patients, especially those suffering from uremic pruritus (itch associated with chronic kidney disease), already show impaired renal function and further stress should be avoided if possible. However, in order to counteract the large concentrations of urea and the reactive isocyanates therefrom, large doses of scavenging molecules are believed to be necessary.

[0062] Thus, in preferred embodiments, the compound has a poor transdermal penetration potential. Thus, a topical formulation for use in the treatment or prevention of itchy dry skin caused by urea, such as in patients with uremic pruritus (chronic kidney disease-associated pruritus), is less likely to enter the systemic circulation and, therefore, less likely to cause further renal stress.

[0063] In a more preferred embodiment, the compound has a poor transdermal penetration potential and is actively converted to more benign degradation products (i.e., amino acids), the vast majority of which are endogenously present, so that topical formulations for use in treating or preventing urea-induced itchy dry skin, such as in patients with uremic pruritus (chronic kidney disease-associated pruritus), are less likely to enter the systemic circulation and, therefore, less likely to cause further renal stress. In addition, if the compound enters the systemic circulation, it is likely to be less likely to enter the systemic circulation due to its benign degradation products and their exposure / concentration profiles being less acute (C 最大 and T 最大 is inhibited), it will be less likely to cause further renal stress. Of note, intravenous administration of the dipeptide Ala-Gln as part of a clinical nutritional regimen in patients with a high catabolic and / or hypermetabolic state is contraindicated in patients with severe renal impairment. (17)

[0064] It is well known in the art that compounds of a given molecular weight with more extreme log P values ​​are less likely to penetrate the skin barrier well. Either extremely hydrophilic (LogP < -2) or extremely hydrophobic (LogP > 2) (16). All dipeptides have a molecular weight below 400, so their LogP is a good approximation of their relative osmotic potential. According to the Log P values ​​calculated by ACD / Labs, Ala-Gln is the most hydrophilic in nature, with a LogP of -4.4.

[0065] In one embodiment of the topical preparation for use according to the invention, the compound has a LogP value of less than -2, preferably less than -4.

[0066] In a preferred embodiment, the compound is the dipeptide Ala-Gln.

[0067] To determine which dipeptides are susceptible to degradation by proteases and other cellular processes in the skin, a number of compounds were tested in skin homogenate studies as described below and the results are listed in Table 3.

[0068] Skin Homogenate Studies:

[0069] Skin from humans with dermatomed from multiple skin donors was collected, homogenized, and adjusted to a tissue concentration of 100 mg of tissue per mL of homogenate. The homogenates were used immediately after preparation without any additional freeze / thaw cycles. Working solutions of each compound were prepared at 40 μg / mL in Dulbecco's phosphate buffered saline (DPBS). All solutions were preheated to 37°C. Equal volumes of skin homogenate and compound working solutions were combined, mixed, stored at 37°C, and sampled at 0, 15, 30, 60, 120, and 240 minutes. The samples were quenched with acidic acetonitrile, centrifuged, and prepared for LC-MS / MS analysis. The peak area of ​​each compound at each time point was determined by LC-MS / MS.

[0070] The individual half-life of each dipeptide was determined.

[0071] Table 3.

[0072]

[0073]

[0074] *Not applicable – defined as >50 min half-life in skin homogenate, or <95% after 3 months at 40°C, poor solubility / potentially high permeability (LogP>-2)

[0075] The nature of the experiments should be considered as an indication of the relative stability of each compound and not an absolute correlation to what will occur in vivo. The process of homogenizing the skin may greatly accelerate degradation. However, it is clear that there is a great deal of variability in the relative rates of each dipeptide. (See Table 3)

[0076] Ala-Gln was one of the compounds with the shortest half-lives measured (<5 minutes), while some of the other dipeptides did not show any degradation during the experimental period (480 minutes). This is arguably in favor of Ala-Gln because, even if there is endogenous amounts in normal skin, any compound that enters the body after topical application is likely to be in the form of its constituent amino acids. Even if all the applied doses were split and entered the systemic system, the endogenous levels of a single amino acid are unlikely to change significantly. Furthermore, the dipeptides were significantly more effective as scavengers than their constituent amino acids, see Tables 1 and 2, an example being Ala-Gln having a degree of carbamylation (% relative to HBSS control) of 34.8, while alanine has a degree of carbamylation (% relative to HBSS control) of 93.54, and glutamine has a degree of carbamylation (% relative to HBSS control) of 74.39.

[0077] The dipeptides showed significant differences in aqueous stability. An important aspect of formulating stable topical products. The data in Table 4 below gives stability data for 1 month and 3 months at 40°C. The compounds were dissolved in HBSS buffer at 3% wt / wt or 0.4% wt / wt (if 3% was not possible) and stored in glass bottles at temperature. The samples were subsequently analyzed by HPLC-UV.

[0078] Table 4. Aqueous stability data

[0079]

[0080]

[0081] As can be seen from the data shown in Tables 1-4 above, there is a wide variation in the performance of different compounds, which makes predictions difficult. Despite the apparent similarities between the dipeptides, surprisingly few possible combinations meet all of the necessary performance criteria. The dipeptides Ala-Gln, Ala-Glu, and Gly-Arg show a combination of good clearance potential, poor transdermal penetration, good aqueous stability, good solubility, and rapid in vivo degradation. In addition, these dipeptides are based on natural amino acids, which allows confidence in their toxicity profiles, as most natural amino acids and their dipeptides will be present in healthy skin at some endogenous level.

[0082] In normal skin, many proteins involved in barrier formation are pH-dependent and are active only in the acidic environment created by UCA in the upper epidermis / stratum corneum (10). In addition to maintaining this homeostasis, reduced pH in the stratum corneum directly inhibits microbial infection and growth (11). It is known that filaggrin deficiency may result in reduced amino acid content in the stratum corneum, including reduced levels of histidine, which in turn may lead to reduced levels of trans-UCA and abnormally high pH. Above-optimal pH in the stratum corneum is thought to reduce pH-dependent lipid-handling enzymes (e.g., β-glucocerebrosidase) and impair barrier function and repair (12).

[0083] However, this study does not involve solving the physiological reasons for defective filaggrin in patients with skin diseases. Instead, the inventors have found that the use of compounds according to formula 1 and / or derivatives thereof as active ingredients in the use of the present invention appears to compensate for defective filaggrin caused by high concentrations of urea in the skin of patients with uremic pruritus. There are currently few methods for preventing and / or treating uremic pruritus.

[0084] In addition, when formula 1 obtains a dipeptide and / or its derivatives, such a dipeptide exhibits low or no mammalian toxicity or reported side effects at conventional doses. Therefore, the use of the included dipeptide and / or its derivatives as active ingredients provides advantages in use, including easy access to patients, improved patient compliance, increased use of the active ingredient in a wide range of patient populations, and longer uninterrupted treatment regimens compared to currently used alternative drugs. In addition, the dipeptide and / or its derivatives are expected to be used to treat the entire body surface of the patient and can be effective against a wide range of skin diseases (particularly inflammatory skin diseases). Preferably, this skin disease is caused by the presence of urea or urine, and includes but is not limited to urostomy dermatitis, incontinence dermatitis and diaper dermatitis, and more preferably uremic pruritus.

[0085] The inventor's new discovery is that high urea concentration interferes with the normal function of proteins and amino acids. In addition, high concentrations of urea have an adverse effect on pH regulation.

[0086] The compound according to Formula 1 including the dipeptide and / or its derivatives may be used as described herein in any suitable form, such as the forms discussed herein.

[0087] The compounds according to formula 1 including dipeptides and / or derivatives thereof can be used as a single therapy or in combination with conventional therapy for the prevention and / or treatment of uremic pruritus. Suitable conventional therapy includes, but is not limited to, treatment with steroids (e.g., steroids for topical administration) and / or with suitable lipids and / or with phototherapy.

[0088] The present invention further provides the use of a topical formulation as described above for treating or preventing pruritus in aged skin of elderly persons.

[0089] The pharmaceutical composition for topical administration according to the invention may be in the form of, for example, a solution, cream, ointment, pectin, gel, spray, foam, powder, liposome or an aqueous or oily solution or suspension.

[0090] In the case of topical application to the scalp, the pharmaceutical composition can be formulated as a shampoo or conditioner. In the case of topical application to the skin, the pharmaceutical composition can be formulated as an additive to cleaning and bathing products (e.g., bath or shower gels and creams). Such pharmaceutical compositions for topical administration may include a diluent or carrier that is also suitable for use in cosmetics.

[0091] Pharmaceutical compositions for topical administration by application to the skin may include moisturizers, and sunscreens and creams.

[0092] Pharmaceutical compositions for topical administration may be provided in any suitable dispenser.

[0093] In the case of pharmaceutical compositions for topical administration by application to the skin, the diluent or carrier should be selected to assist in the transport of the active ingredient through the skin barrier and may need to be able to pass through the stratum corneum of the skin. Many methods for preparing pharmaceutical compositions for topical administration are known. For example, the active ingredient can be mixed with a known carrier material.

[0094] Alternatively, the skilled artisan will appreciate that topical administration may be achieved by local injection, such as intradermal injection.

[0095] The pharmaceutical composition of the present invention can be obtained by conventional procedures using conventional pharmaceutical diluents or carriers well known in the art.

[0096] References

[0097] 1Fitzpatricks.Dermatology in general medicine.Eds.Freedberg IM etal.Six eds 2003,p 400.

[0098] 2Harrisons principles of internal medicine.Eds.Kasper et al 16th eds2005.Chronic renal failure p 1653.

[0099] 3Fitzpatricks.Dermatology in general medicine.Eds.Freedberg IM et alsix eds.2003,p103.

[0100] 4Al-Tamer YY,Hadi EA,al Badrani II.Ural.Res.1997;25:337-40.

[0101] 5Fitzpatricks.Dermatology in general medicine.Eds.Freedberg IM etal.Six eds 2003,p 109.

[0102] 6Kezic S.Functions of filaggrin and its metabolites.In Flaggrin.EdsThyssen JP and Maibach HI.2014;p3-9.

[0103] 7Kezic S,O'Regan GM,YanN et al.Levels of filaggrin degradationproducts are influenced by both filaggrin genotype and atopic dermatitisseverity.Allergy.2011;66:934-940.

[0104] 8 Nozaki Y and Tanford C.The solubility of amino acids andrelatedcompounds in aqueous urea solutions.J.Biol.Chem.1963;238:4074-4081.

[0105] 9 Stark G.R and Smyth D.G.The use of cyanate for the determinationofNH2-terminal residues in proteins.J.Biol.Chem.1963,238:214-226

[0106] 10 Schmid-Wendtner MH and Korting HC,Skin Pharmacol.Physiol.2006:19:296-302

[0107] 11 Rippke et al,Am.J.Clin.Dermatol.2004;5:217-23

[0108] 12 Mauro et al,Arch.Dermatol.Res.1998;290:215-22

[0109] 13 Moss E et al.In situ metabolism of chinamyl alcohol inreconstructedhuman epidermis:New insigths into the activation of thisfragrance sensitizer.Chem.Res.Toxicol.2016;29:1172-8.

[0110] 14 Bandier J et al.Quantification of epidermal filaggrin in humanskin andits response to skin irritation.J.Invest Dermatol.2015;136:1519-29.

[0111] 15 G.R.Stark.Reactions of Cyanate with Functional Groups ofProteins.III.Reactions with Amino and Carboxyl Groups.Biochemistry 1965;4:1030-1036

[0112] 16 Tsakovska I,Pajeva I,Al Sharif M,Alov P,Fioravanzo E,Kovarich S,Worth AP,Richarz AN,Yang C,Mostrag-Szlichtyng A,Cronin MTD.Quantitativestructure-skin permeability relationships.Toxicology.2017 Jul15;387:27-42.doi:10.1016 / j.tox.2017.06.008.Epub 2017 Jun 21.PMID:28645577

[0113] 17 Dipeptevin Data sheet.https: / / www.fresenius-kabi.com / nz / documents / Dipeptiven_Datasheet.pdf。

Claims

1. A topical preparation for the treatment or prevention of itchy dry skin caused by urea, in, The topical formulation comprises a compound selected from the group consisting of: N-β-aminoethyl-Gly, Lys-Pro, Val-Pro, Ile-Pro, Tyr-Pro, Ala-Gln, Ala-Glu, Tyr-Ala, Val-Tyr, Gly-Ser, Gly-His and aspartame; or alternatively Gly-Arg.

2. A topical preparation for use according to claim 1, in, The compound is Ala-Gln, Ala-Glu or Gly-Arg.

3. A topical preparation for use according to any one of the preceding claims, in, The compound is selected from the group consisting of Ala-Gln and Ala-Glu.

4. A topical preparation for use according to any one of the preceding claims, in, The compound is Ala-Gln.

5. A topical preparation for use according to any one of the preceding claims, in, The compound is Ala-Glu.

6. A topical preparation for use according to any one of the preceding claims, in, The compound has a LogP value of less than -2; more preferably, wherein the compound has a LogP value of less than -4.

7. A topical preparation for use according to any one of the preceding claims, in, The urea-induced itchy and dry skin is selected from the group consisting of uremic pruritus, urostomy dermatitis, incontinence dermatitis, and diaper dermatitis.

8. A topical formulation for use according to any one of the preceding claims for the treatment or prevention of pruritus in aged skin of elderly people.

9. A topical formulation for use according to any one of claims 1 to 7 for the treatment or prevention of uremic pruritus.

10. A topical formulation for use according to any one of the preceding claims, in, The compounds produce a degree of BSA carbamylation of less than 80%, preferably less than 70%, more preferably less than 60%, even more preferably less than 50%, as measured by the in vitro protein carbamylation assay provided herein.

11. A topical preparation for use according to any one of the preceding claims, in, The compound and / or a pharmaceutically acceptable salt thereof is present in the topical formulation in an amount between 0.1% (w / w) and 20.0% (w / w), preferably between 0.2% (w / w) and 5.0% (w / w), more preferably between 0.3% (w / w) and 4.0% (w / w).

12. A topical formulation for use according to any one of the preceding claims, in, The compound and / or a pharmaceutically acceptable salt thereof is present in the topical formulation in an amount between 0.5% (w / w) and 20.0% (w / w), preferably between 1% (w / w) and 10% (w / w), more preferably between 2% (w / w) and 5.0% (w / w).

13. A topical formulation for use according to any one of the preceding claims, in, The compound has an aqueous stability of greater than 95% after 3 months at 40°C.

Citation Information

Patent Citations

  • Process for isolating rubbers

    EP0002015A1

  • Compositions comprising n-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof

    US20090186853A1

  • Activation of TRPV4 ion channel by physical stimuli and critical role for TRPV4 in organ-specific inflammation and itch

    US20150252035A1

  • Compounds for preventing, reducing and / or alleviating itchy skin condition(s)

    US20160008297A1